Kriya Therapeutics to Advance Gene Therapies with $100 Million Financing
Kriya Therapeutics completes $100 Million Series B financing to advance its platform for designing, developing, and manufacturing gene therapies.
Kriya Therapeutics announced in a July 14, 2021 press release the closing of a $100 million Series B financing to support the design, development, and manufacturing of gene therapies.
According to the press release, the financing proceeds will be used to further develop Kriya’s core technology platforms, expand its therapeutic pipeline, and advance its current programs in metabolic disease, ophthalmology, and oncology.
“With the support of our new and existing investors, we believe that Kriya is well positioned to deliver transformative improvements in cost, scale, and efficiency that will help the gene therapy field achieve its full potential across a range of therapeutic areas,” said Shankar Ramaswamy, co-founder and CEO of Kriya Therapeutics, in a press release.
The financing was led by Patient Square Capital, with participation from Woodline Partners LP, CAM Capital, Hongkou, Alumni Ventures, and other new investors. All existing institutional investors also participated.
Source: Kriya Therapeutics
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
PostEra Expands Pfizer Partnership with AI Lab and ADC Collaborations
January 8th 2025The AI Lab was launched almost exactly three years ago and has produced several programs so far, at least one of which achieved its first scientific stage gate 40% faster than the teams originally forecasted.
